Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Natera, Inc. or Exact Sciences Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Natera, Inc. and Exact Sciences Corporation compare based on key financial metrics to determine which better meets your investment needs.
About Natera, Inc. and Exact Sciences Corporation
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Latest Biotechnology and Natera, Inc., Exact Sciences Corporation Stock News
As of May 5, 2025, Natera, Inc. had a $21.4 billion market capitalization, compared to the Biotechnology median of $111.9 million. Natera, Inc.’s stock is down 1.8% in 2025, up 0.4% in the previous five trading days and up 67.16% in the past year.
Currently, Natera, Inc. does not have a price-earnings ratio. Natera, Inc.’s trailing 12-month revenue is $1.7 billion with a -11.2% net profit margin. Year-over-year quarterly sales growth most recently was 53.0%. Analysts expect adjusted earnings to reach $-2.219 per share for the current fiscal year. Natera, Inc. does not currently pay a dividend.
As of May 5, 2025, Exact Sciences Corporation had a $10.1 billion market cap, putting it in the 81st percentile of all stocks. Exact Sciences Corporation’s stock is down 3.9% in 2025, up 20.5% in the previous five trading days and down 11.13% in the past year.
Currently, Exact Sciences Corporation does not have a price-earnings ratio. Exact Sciences Corporation’s trailing 12-month revenue is $2.8 billion with a -36.1% net profit margin. Year-over-year quarterly sales growth most recently was 10.9%. Analysts expect adjusted earnings to reach $0.225 per share for the current fiscal year. Exact Sciences Corporation does not currently pay a dividend.
How We Compare Natera, Inc. and Exact Sciences Corporation Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Natera, Inc. and Exact Sciences Corporation’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions